Pfizer PFE is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer ...

AstraZeneca, Pfizer and more are leveraging the computational power of AI to better design trials, predict the potential ...

Dublin, March 24, 2025 (GLOBE NEWSWIRE) -- The "Global Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030" report has been added to ...

The debate between CAR T-cell therapy and bispecific antibodies is not a rivalry but a question of sequencing, ...

Merck MRK announced FDA approval for its prophylactic long-acting monoclonal antibody, clesrovimab, for the prevention of RSV ...

Pfizer’s Chinese drug acquisition: The pharma giant spent $1.25 billion to acquire an experimental PD1-VEGF antibody from Chinese ... analysts and investors. AstraZeneca’s plenary streak ...

AstraZeneca has shared an early look at the performance of its in-house antibody-drug conjugate (ADC ... compete with molecules from AbbVie and Pfizer. The Anglo-Swedish drugmaker is a leading ...

Surovatamig shows promise, but needs to outperform established therapies such as Blincyto and Aucatzyl.

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, Medicare patients.

Sanofi and AstraZeneca are closing in on EU approval of nirsevimab, their long-acting antibody for the protection ... for RSV prevention reach the market. Pfizer is currently leading the race ...

Merck’s Enflonsia will go up against Sanofi and AstraZeneca’s Beyfortus, which the partners plan to ship out early in the ...

Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly ...